Clinical Trial Update: Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating frontline zanubrutinib plus rituximab for mucosa-associated lymphoid tissue lymphoma (MALT) is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucosa-associated Lymphoid Tissue Lymphoma

Drugs mentioned

• BRUKINSA (ZANUBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Mucosa-associated Lymphoid Tissue Lymphoma (MALT) | Phase 2 | Status: RECRUITING